

ALGERIA, 5 registries (1996-2014)

	Number of cases							Percentage				Incidence rates per million person-years								MV % 0-19	DCO % 0-19	
	Age group							0-14		0-19		Age-specific					Cumulative					
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	ASR	0-19			0-14
I LEUKAEMIA	11	152	131	96	129	390	519	23.5	100.0	19.7	100.0	9.3	33.3	23.7	15.7	19.0	23.2	22.2	339	434	98.1	1.7
a. Lymphoid	2	86	63	42	52	193	245	11.6	49.5	9.3	47.2	1.7	18.8	11.4	6.9	7.6	11.6	10.7	168	206	99.2	0.8
b. Acute myeloid	5	24	32	29	42	90	132	5.4	23.1	5.0	25.4	4.2	5.3	5.8	4.7	6.2	5.2	5.4	78	109	97.7	1.5
c. CMD	1	3	1	0	13	5	18	0.3	1.3	0.7	3.5	0.8	0.7	0.2	-	1.9	0.3	0.7	4	14	100.0	0.0
d. MDS & other	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
e. Unspecified	3	39	35	25	22	102	124	6.2	26.2	4.7	23.9	2.5	8.5	6.3	4.1	3.2	6.1	5.4	89	105	96.0	4.0
II LYMPHOMA & RELATED	3	72	99	136	253	310	563	18.7	100.0	21.3	100.0	2.5	15.8	17.9	22.2	37.2	17.3	21.8	266	452	98.4	1.4
a. Hodgkin	1	15	42	65	174	123	297	7.4	39.7	11.3	52.8	0.8	3.3	7.6	10.6	25.6	6.6	10.9	105	233	99.3	0.7
b. Non-Hodgkin except BL	2	36	45	48	64	131	195	7.9	42.3	7.4	34.6	1.7	7.9	8.2	7.9	9.4	7.5	7.9	113	160	97.9	2.1
c. Burkitt (BL)	0	10	7	2	4	19	23	1.1	6.1	0.9	4.1	-	2.2	1.3	0.3	0.6	1.2	1.0	17	20	95.7	4.3
d. Lymphoreticular	0	3	0	1	0	4	4	0.2	1.3	0.2	0.7	-	0.7	-	0.2	-	0.2	0.2	3	3	100.0	0.0
e. Unspecified	0	8	5	20	11	33	44	2.0	10.6	1.7	7.8	-	1.8	0.9	3.3	1.6	1.8	1.7	28	36	95.5	2.3
III CNS NEOPLASMS †	4	64	79	77	89	224	313	13.5	100.0	11.9	100.0	3.4	14.0	14.3	12.6	13.1	12.9	12.9	194	259	70.9	5.4
a. Ependymoma	0	5	0	1	2	6	8	0.4	2.7	0.3	2.6	-	1.1	-	0.2	0.3	0.4	0.4	5	7	100.0	0.0
b. Astrocytoma	1	10	22	21	25	54	79	3.3	24.1	3.0	25.2	0.8	2.2	4.0	3.4	3.7	3.0	3.2	47	65	98.7	1.3
c. CNS embryonal	0	17	19	21	8	57	65	3.4	25.4	2.5	20.8	-	3.7	3.4	3.4	1.2	3.3	2.8	49	55	100.0	0.0
d. Other gliomas	0	8	9	8	9	25	34	1.5	11.2	1.3	10.9	-	1.8	1.6	1.3	1.3	1.4	1.4	22	28	97.1	0.0
e. Other specified	1	0	1	2	6	4	10	0.2	1.8	0.4	3.2	0.8	-	0.2	0.3	0.9	0.2	0.4	3	8	100.0	0.0
f. Unspecified CNS	2	24	28	24	39	78	117	4.7	34.8	4.4	37.4	1.7	5.3	5.1	3.9	5.7	4.5	4.8	68	96	23.9	13.7
IV NEUROBLASTOMA	10	75	18	9	6	112	118	6.8	100.0	4.5	100.0	8.5	16.4	3.3	1.5	0.9	7.2	5.8	98	102	89.0	1.7
a. (Ganglio)neuroblastoma	10	75	18	9	5	112	117	6.8	100.0	4.4	99.2	8.5	16.4	3.3	1.5	0.7	7.2	5.7	98	101	88.9	1.7
b. Peripheral nervous	0	0	0	0	1	0	1	-	-	0.0	0.8	-	-	-	-	0.1	-	0.0	-	1	100.0	0.0
V RETINOBLASTOMA	7	15	5	0	1	27	28	1.6	100.0	1.1	100.0	5.9	3.3	0.9	-	0.1	1.8	1.4	24	24	71.4	0.0
VI RENAL TUMOURS	4	86	29	12	4	131	135	7.9	100.0	5.1	100.0	3.4	18.8	5.3	2.0	0.6	8.3	6.6	114	117	96.3	0.7
a. Nephroblastoma	4	82	27	11	1	124	125	7.5	94.7	4.7	92.6	3.4	18.0	4.9	1.8	0.1	7.9	6.1	108	109	99.2	0.8
b. Renal carcinoma	0	0	1	0	3	1	4	0.1	0.8	0.2	3.0	-	-	0.2	-	0.4	0.1	0.1	1	3	100.0	0.0
c. Unspecified	0	4	1	1	0	6	6	0.4	4.6	0.2	4.4	-	0.9	0.2	0.2	-	0.4	0.3	5	5	33.3	0.0
VII HEPATIC TUMOURS	4	7	1	1	3	13	16	0.8	100.0	0.6	100.0	3.4	1.5	0.2	0.2	0.4	0.8	0.8	11	13	68.8	6.3
a. Hepatoblastoma	2	5	1	1	0	9	9	0.5	69.2	0.3	56.3	1.7	1.1	0.2	0.2	-	0.6	0.4	8	8	88.9	11.1
b. Hepatic carcinoma	0	0	0	0	2	0	2	-	-	0.1	12.5	-	-	-	-	0.3	-	0.1	-	1	100.0	0.0
c. Unspecified	2	2	0	0	1	4	5	0.2	30.8	0.2	31.3	1.7	0.4	-	-	0.1	0.3	0.2	3	4	20.0	0.0
VIII BONE TUMOURS	0	13	28	86	120	127	247	7.7	100.0	9.4	100.0	-	2.8	5.1	14.1	17.7	6.6	9.1	107	195	96.4	0.8
a. Osteosarcoma	0	5	15	45	69	65	134	3.9	51.2	5.1	54.3	-	1.1	2.7	7.4	10.1	3.4	4.9	55	105	98.5	0.7
b. Chondrosarcoma	0	0	0	5	5	5	10	0.3	3.9	0.4	4.0	-	-	-	0.8	0.7	0.2	0.3	4	8	100.0	0.0
c. Ewing & related	0	2	8	20	26	30	56	1.8	23.6	2.1	22.7	-	0.4	1.5	3.3	3.8	1.6	2.1	25	44	100.0	0.0
d. Other specified	0	0	0	3	3	3	6	0.2	2.4	0.2	2.4	-	-	-	0.5	0.4	0.1	0.2	2	5	100.0	0.0
e. Unspecified	0	6	5	13	17	24	41	1.4	18.9	1.6	16.6	-	1.3	0.9	2.1	2.5	1.3	1.6	20	33	82.9	2.4
IX SOFT TISSUE SARCOMA	2	42	20	25	50	89	139	5.4	100.0	5.3	100.0	1.7	9.2	3.6	4.1	7.4	5.3	5.8	77	114	98.6	0.7
a. Rhabdomyosarcoma	1	34	11	10	10	56	66	3.4	62.9	2.5	47.5	0.8	7.4	2.0	1.6	1.5	3.5	3.0	49	56	97.0	1.5
b. Fibrosarcoma	0	1	1	6	11	8	19	0.5	9.0	0.7	13.7	-	0.2	0.2	1.0	1.6	0.4	0.7	7	15	100.0	0.0
c. Kaposi sarcoma	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
d. Other specified	1	4	3	7	17	15	32	0.9	16.9	1.2	23.0	0.8	0.9	0.5	1.1	2.5	0.8	1.2	13	25	100.0	0.0
e. Unspecified	0	3	5	2	12	10	22	0.6	11.2	0.8	15.8	-	0.7	0.9	0.3	1.8	0.6	0.9	9	18	100.0	0.0
X GERM CELL TUMOURS	4	6	4	11	32	25	57	1.5	100.0	2.2	100.0	3.4	1.3	0.7	1.8	4.7	1.4	2.2	21	45	93.0	0.0
a. CNS germ cell	0	0	1	3	0	4	4	0.2	16.0	0.2	7.0	-	-	0.2	0.5	-	0.2	0.2	3	3	100.0	0.0
b. Other extragonadal	1	1	1	2	3	5	8	0.3	20.0	0.3	14.0	0.8	0.2	0.2	0.3	0.4	0.3	0.3	4	6	100.0	0.0
c. Gonadal germ cell	2	2	1	4	15	9	24	0.5	36.0	0.9	42.1	1.7	0.4	0.2	0.7	2.2	0.5	0.9	8	19	100.0	0.0
d. Gonadal carcinoma	0	2	1	0	11	3	14	0.2	12.0	0.5	24.6	-	0.4	0.2	-	1.6	0.2	0.5	3	11	100.0	0.0
e. Unspecified gonadal	1	1	0	2	3	4	7	0.2	16.0	0.3	12.3	0.8	0.2	-	0.3	0.4	0.2	0.3	3	6	42.9	0.0
XI CARCINOMA & MELANOMA	2	12	23	76	232	113	345	6.8	100.0	13.1	100.0	1.7	2.6	4.2	12.4	34.1	5.9	12.2	95	266	98.8	0.3
a. Adrenocortical	0	0	0	0	1	0	1	-	-	0.0	0.3	-	-	-	-	0.1	-	0.0	-	1	100.0	0.0
b. Thyroid	0	1	4	13	33	18	51	1.1	15.9	1.9	14.8	-	0.2	0.7	2.1	4.9	0.9	1.8	15	39	100.0	0.0
c. Nasopharyngeal	1	0	4	29	88	34	122	2.1	30.1	4.6	35.4	0.8	-	0.7	4.7	12.9	1.7	4.2	28	93	99.2	0.0
d. Melanoma	0	0	1	0	3	1	4	0.1	0.9	0.2	1.2	-	-	0.2	-	0.4	0.1	0.1	1	3	100.0	0.0
e. Skin carcinoma	0	3	5	6	13	14	27	0.8	12.4	1.0	7.8	-	0.7	0.9	1.0	1.9	0.8	1.0	12	22	96.3	0.0
f. Other & unspecified	1	8	9	28	94	46	140	2.8	40.7	5.3	40.6	0.8	1.8	1.6	4.6	13.8	2.5	5.0	39	108	98.6	0.7
XII OTHER & UNSPECIFIED	3	31	26	37	63	97	160	5.9	100.0	6.1	100.0	2.5	6.8	4.7	6.1	9.3	5.6	6.4	83	130	60.0	1.9
a. Other specified	0	2	0	1	0	3	3	0.2	3.1	0.1	1.9	-	0.4	-	0.2	-	0.2	0.1	3	3	100.0	0.0
b. Other unspecified	3	29	26	36	63	94	157	5.7	96.9	5.9	98.1	2.5	6.4	4.7	5.9	9.3	5.4	6.3	81	127	59.2	1.9
TOTAL	54	575	463	566	982	1658	2640	100.0	100.0	100.0	100.0	45.7	125.9	83.9	92.6	144.4	96.3	107.1	1430	2152	91.5	1.7

† includes 15 non-malignant

Please consult the quality indicators for the constituent registries

ALGERIA, 5 registries (1996-2014)

	Males										M/F ratio		Females											
	Number of cases in age groups										0-14	0-19	Number of cases in age groups										0-14	0-19
	0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19			0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19		
I LEUKAEMIA	4	89	92	54	79	239	318	27.9	26.7	1.6	1.6	7	63	39	42	50	151	201	18.3	17.6				
a. Lymphoid	0	55	48	25	34	128	162	15.1	13.9	2.0	2.0	2	31	15	17	18	65	83	8.0	7.4				
b. Acute myeloid	2	10	21	12	26	45	71	5.1	5.7	1.0	1.2	3	14	11	17	16	45	61	5.3	5.2				
c. CMD	1	2	0	0	5	3	8	0.4	0.6	1.5	0.8	0	1	1	0	8	2	10	0.3	0.7				
d. MDS & other	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-				
e. Unspecified	1	22	23	17	14	63	77	7.3	6.5	1.6	1.6	2	17	12	8	8	39	47	4.8	4.3				
II LYMPHOMA & RELATED	0	63	71	78	116	212	328	23.7	25.9	2.2	1.4	3	9	28	58	137	98	235	10.6	17.4				
a. Hodgkin	0	13	25	36	77	74	151	7.9	11.2	1.5	1.0	1	2	17	29	97	49	146	5.2	10.6				
b. Non-Hodgkin except BL	0	33	36	29	30	98	128	11.2	10.6	3.0	1.9	2	3	9	19	34	33	67	3.6	5.1				
c. Burkitt (BL)	0	8	6	2	3	16	19	1.9	1.7	5.3	4.8	0	2	1	0	1	3	4	0.4	0.4				
d. Lymphoreticular	0	2	0	0	0	2	2	0.3	0.2	1.0	1.0	0	1	0	1	0	2	2	0.2	0.2				
e. Unspecified	0	7	4	11	6	22	28	2.4	2.3	2.0	1.8	0	1	1	9	5	11	16	1.1	1.2				
III CNS NEOPLASMS †	3	36	50	39	43	128	171	14.5	14.0	1.3	1.2	1	28	29	38	46	96	142	11.1	11.7				
a. Ependymoma	0	1	0	0	2	1	3	0.1	0.2	0.2	0.6	0	4	0	1	0	5	5	0.6	0.5				
b. Astrocytoma	1	8	11	11	11	31	42	3.5	3.4	1.3	1.1	0	2	11	10	14	23	37	2.6	2.9				
c. CNS embryonal	0	9	17	13	3	39	42	4.3	3.6	2.2	1.8	0	8	2	8	5	18	23	2.1	2.0				
d. Other gliomas	0	5	4	2	6	11	17	1.3	1.4	0.8	1.0	0	3	5	6	3	14	17	1.6	1.4				
e. Other specified	1	0	1	2	2	4	6	0.4	0.5	-	1.5	0	0	0	0	4	0	4	-	0.3				
f. Unspecified CNS	1	13	17	11	19	42	61	4.8	5.0	1.2	1.1	1	11	11	13	20	36	56	4.2	4.6				
IV NEUROBLASTOMA	9	42	8	5	5	64	69	8.1	6.6	1.3	1.4	1	33	10	4	1	48	49	6.3	4.9				
a. (Ganglioneuroblastoma	9	42	8	5	4	64	68	8.1	6.5	1.3	1.4	1	33	10	4	1	48	49	6.3	4.9				
b. Peripheral nervous	0	0	0	0	1	0	1	-	0.1	-	-	0	0	0	0	0	0	0	-	-				
V RETINOBLASTOMA	3	3	2	0	1	8	9	1.0	0.9	0.4	0.5	4	12	3	0	0	19	19	2.6	2.0				
VI RENAL TUMOURS	1	44	14	6	1	65	66	8.1	6.3	1.0	1.0	3	42	15	6	3	66	69	8.6	6.8				
a. Nephroblastoma	1	42	13	5	0	61	61	7.6	5.9	1.0	1.0	3	40	14	6	1	63	64	8.2	6.4				
b. Renal carcinoma	0	0	1	0	1	1	2	0.1	0.2	-	1.0	0	0	0	0	2	0	2	-	0.1				
c. Unspecified	0	2	0	1	0	3	3	0.4	0.3	1.0	1.0	0	2	1	0	0	3	3	0.4	0.3				
VII HEPATIC TUMOURS	2	5	0	1	1	8	9	1.0	0.9	1.6	1.3	2	2	1	0	2	5	7	0.7	0.7				
a. Hepatoblastoma	2	4	0	1	0	7	7	0.9	0.7	3.5	3.5	0	1	1	0	0	2	2	0.3	0.2				
b. Hepatic carcinoma	0	0	0	0	1	0	1	-	0.1	-	1.0	0	0	0	0	1	0	1	-	0.1				
c. Unspecified	0	1	0	0	0	1	1	0.1	0.1	0.3	0.3	2	1	0	0	1	3	4	0.4	0.4				
VIII BONE TUMOURS	0	8	13	57	76	78	154	7.9	11.0	1.6	1.7	0	5	15	29	44	49	93	5.3	7.1				
a. Osteosarcoma	0	2	6	32	45	40	85	3.9	6.0	1.6	1.7	0	3	9	13	24	25	49	2.7	3.7				
b. Chondrosarcoma	0	0	0	3	3	3	6	0.3	0.4	1.5	1.5	0	0	0	2	2	2	4	0.2	0.3				
c. Ewing & related	0	2	4	11	17	17	34	1.7	2.5	1.3	1.5	0	0	4	9	9	13	22	1.3	1.7				
d. Other specified	0	0	0	2	2	2	4	0.2	0.3	2.0	2.0	0	0	0	1	1	1	2	0.1	0.1				
e. Unspecified	0	4	3	9	9	16	25	1.7	1.9	2.0	1.6	0	2	2	4	8	8	16	0.9	1.2				
IX SOFT TISSUE SARCOMA	0	25	12	16	26	53	79	6.2	6.5	1.5	1.3	2	17	8	9	24	36	60	4.4	5.1				
a. Rhabdomyosarcoma	0	19	6	6	5	31	36	3.8	3.2	1.2	1.2	1	15	5	4	5	25	30	3.2	2.8				
b. Fibrosarcoma	0	1	0	3	3	4	7	0.4	0.5	1.0	0.6	0	0	1	3	8	4	12	0.4	0.9				
c. Kaposi sarcoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-				
d. Other specified	0	2	2	5	9	9	18	1.0	1.3	1.5	1.3	1	2	1	2	8	6	14	0.7	1.1				
e. Unspecified	0	3	4	2	9	9	18	1.0	1.4	9.0	4.5	0	0	1	0	3	1	4	0.1	0.3				
X GERM CELL TUMOURS	3	4	0	4	12	11	23	1.3	1.8	0.8	0.7	1	2	4	7	20	14	34	1.6	2.6				
a. CNS germ cell	0	0	0	3	0	3	3	0.3	0.2	3.0	3.0	0	0	1	0	0	1	1	0.1	0.1				
b. Other extragonadal	1	0	0	1	2	2	4	0.2	0.3	0.7	1.0	0	1	1	1	1	3	4	0.4	0.3				
c. Gonadal germ cell	2	2	0	0	9	4	13	0.5	1.0	0.8	1.2	0	0	1	4	6	5	11	0.5	0.8				
d. Gonadal carcinoma	0	1	0	0	1	1	2	0.1	0.2	0.5	0.2	0	1	1	0	10	2	12	0.3	0.9				
e. Unspecified gonadal	0	1	0	0	0	1	1	0.1	0.1	0.3	0.2	1	0	0	2	3	3	6	0.3	0.5				
XI CARCINOMA & MELANOMA	1	6	15	42	126	64	190	6.6	13.3	1.3	1.2	1	6	8	34	106	49	155	5.2	11.2				
a. Adrenocortical	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.1				
b. Thyroid	0	0	3	3	12	6	18	0.6	1.3	0.5	0.5	0	1	1	10	21	12	33	1.2	2.4				
c. Nasopharyngeal	1	0	2	19	61	22	83	2.1	5.6	1.8	2.1	0	0	2	10	27	12	39	1.2	2.8				
d. Melanoma	0	0	1	0	0	1	1	0.1	0.1	-	0.3	0	0	0	0	3	0	3	-	0.2				
e. Skin carcinoma	0	3	3	3	7	9	16	1.0	1.2	1.8	1.5	0	0	2	3	6	5	11	0.5	0.8				
f. Other & unspecified	0	3	6	17	46	26	72	2.7	5.1	1.3	1.1	1	5	3	11	48	20	68	2.2	5.0				
XII OTHER & UNSPECIFIED	2	15	15	21	31	53	84	5.9	6.6	1.2	1.1	1	16	11	16	32	44	76	5.2	6.2				
a. Other specified	0	2	0	0	0	2	2	0.3	0.2	2.0	2.0	0	0	0	1	0	1	1	0.1	0.1				
b. Other unspecified	2	13	15	21	31	51	82	5.7	6.4	1.2	1.1	1	16	11	15	32	43	75	5.1	6.1				
TOTAL	28	340	292	323	517	983	1500	112.1	120.6	1.5	1.3	26	235	171	243	465	675	1140	79.8	93.2				

† includes 10 non-malignant in males and 5 non-malignant in females

Please consult the quality indicators for the constituent registries

ALGERIA, 5 registries (1996-2014)

	Age group	Males	Females
Person-years	0	602 703	578 985
	1-4	2 332 765	2 234 113
	5-9	2 811 910	2 704 077
	10-14	3 113 997	3 000 037
	15-19	3 455 082	3 343 636
Total	0-14	8 861 375	8 517 212
	0-19	12 316 457	11 860 848
Average annual population	0-14	466 388	448 274
	0-19	648 235	624 255

Please consult the quality indicators for the constituent registries

ALGERIA, 5 registries (1996-2014)

Registry	Period	Cases	%	Person-years	%
Algiers	2008-2012	824	31.2	4 798 135	19.8
Annaba	2000-2010	271	10.3	2 318 530	9.6
Batna	2008-2012	211	8.0	2 374 990	9.8
Sétif	1996-2014	992	37.6	11 588 385	47.9
Tlemcen	2006-2014	342	13.0	3 097 265	12.8
ALGERIA	1996-2014	2640	100.0	24 177 305	100.0

Please consult the quality indicators for the constituent registries

International Incidence of Childhood Cancer Volume III <http://iicc.iarc.fr/results>

Africa

Annaba
(2000-2010)Batna
(2008-2012)

	Annaba (2000-2010)			Annaba (2000-2010)			Batna (2008-2012)			Batna (2008-2012)		
	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR
I LEUKAEMIA	57	1.5	34.4	76	1.6	33.3	42	1.3	25.9	54	1.1	24.0
a. Lymphoid	38	1.4	22.5	48	1.7	20.9	23	2.3	14.9	27	2.4	12.9
b. Acute myeloid	15	2.0	9.2	23	1.9	9.9	16	0.6	9.2	19	0.5	8.1
c. CMD	0	.	.	0	.	.	0	.	.	4	0.3	1.3
d. MDS & other	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified	4	1.0	2.7	5	0.7	2.4	3	2.0	1.8	4	1.0	1.7
II LYMPHOMA & RELATED	37	2.1	21.7	58	1.6	24.1	21	2.0	12.8	48	2.0	18.9
a. Hodgkin	11	0.8	5.9	26	0.7	9.8	6	1.0	3.4	26	2.3	9.2
b. Non-Hodgkin except BL	23	3.6	14.2	28	3.7	12.7	7	2.5	4.5	12	1.0	5.2
c. Burkitt (BL)	0	.	.	0	.	.	5	4.0	3.1	6	5.0	2.7
d. Lymphoreticular	0	.	.	0	.	.	1	0.0	0.5	1	0.0	0.4
e. Unspecified	3	2.0	1.6	4	3.0	1.6	2	.	1.3	3	.	1.3
III CNS NEOPLASMS	24	2.0	14.4	39	1.6	16.3	16	3.0	9.9	24	1.4	10.3
a. Ependymoma	1	0.0	0.7	1	0.0	0.5	0	.	.	0	.	.
b. Astrocytoma	6	2.0	3.5	11	1.8	4.5	2	.	1.3	4	3.0	1.7
c. CNS embryonal	8	3.0	4.8	11	1.2	4.8	5	.	3.2	5	.	2.5
d. Other gliomas	1	0.0	0.5	3	0.5	1.1	0	.	.	1	.	0.3
e. Other specified	0	.	.	0	.	.	0	.	.	0	.	.
f. Unspecified CNS	8	3.0	4.9	13	3.3	5.5	9	1.3	5.4	14	0.6	5.8
IV NEUROBLASTOMA	8	0.3	5.5	10	0.7	5.0	9	3.5	5.9	10	4.0	4.9
a. (Ganglio)neuroblastoma	8	0.3	5.5	10	0.7	5.0	9	3.5	5.9	9	3.5	4.6
b. Peripheral nervous	0	.	.	0	.	.	0	.	.	1	.	0.3
V RETINOBLASTOMA	11	1.2	7.4	12	1.4	6.1	0	.	.	0	.	.
VI RENAL TUMOURS	13	2.3	8.7	13	2.3	6.8	2	1.0	1.3	3	2.0	1.4
a. Nephroblastoma	13	2.3	8.7	13	2.3	6.8	1	0.0	0.7	1	0.0	0.5
b. Renal carcinoma	0	.	.	0	.	.	0	.	.	1	.	0.3
c. Unspecified	0	.	.	0	.	.	1	.	0.7	1	.	0.5
VII HEPATIC TUMOURS	2	.	1.4	3	.	1.4	2	0.0	1.3	4	0.0	1.7
a. Hepatoblastoma	2	.	1.4	2	.	1.1	0	.	.	0	.	.
b. Hepatic carcinoma	0	.	.	1	.	0.3	0	.	.	1	0.0	0.3
c. Unspecified	0	.	.	0	.	.	2	0.0	1.3	3	0.0	1.4
VIII BONE TUMOURS	10	9.0	5.4	20	4.0	7.7	15	2.0	7.6	28	1.8	10.2
a. Osteosarcoma	7	6.0	3.9	14	3.7	5.5	8	3.0	4.0	17	1.8	6.1
b. Chondrosarcoma	0	.	.	0	.	.	1	.	0.5	1	.	0.4
c. Ewing & related	1	.	0.5	3	.	1.1	6	1.0	3.1	10	1.5	3.7
d. Other specified	2	.	1.0	2	.	0.8	0	.	.	0	.	.
e. Unspecified	0	.	.	1	0.0	0.3	0	.	.	0	.	.
IX SOFT TISSUE SARCOMA	11	2.7	6.8	15	1.5	6.6	6	2.0	3.8	13	1.6	5.2
a. Rhabdomyosarcoma	6	5.0	3.9	8	1.7	3.7	3	2.0	1.8	3	2.0	1.4
b. Fibrosarcoma	0	.	.	0	.	.	0	.	.	1	0.0	0.3
c. Kaposi sarcoma	0	.	.	0	.	.	0	.	.	0	.	.
d. Other specified	2	1.0	1.3	2	1.0	1.0	2	1.0	1.3	7	1.3	2.7
e. Unspecified	3	2.0	1.6	5	1.5	1.9	1	.	0.7	2	.	0.8
X GERM CELL TUMOURS	0	.	.	3	0.5	1.0	3	0.5	1.8	4	0.3	1.7
a. CNS germ cell	0	.	.	0	.	.	0	.	.	0	.	.
b. Other extragonadal	0	.	.	0	.	.	1	0.0	0.7	1	0.0	0.5
c. Gonadal germ cell	0	.	.	2	1.0	0.7	1	.	0.7	2	1.0	0.8
d. Gonadal carcinoma	0	.	.	1	0.0	0.3	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	0	.	.	1	0.0	0.5	1	0.0	0.4
XI CARCINOMA & MELANOMA	10	1.5	5.6	20	1.5	7.8	7	1.3	3.5	18	1.0	6.4
a. Adrenocortical	0	.	.	0	.	.	0	.	.	0	.	.
b. Thyroid	2	1.0	1.0	4	1.0	1.5	1	0.0	0.5	3	0.5	1.0
c. Nasopharyngeal	3	2.0	1.6	9	2.0	3.3	2	1.0	1.0	6	1.0	2.1
d. Melanoma	0	.	.	0	.	.	0	.	.	0	.	.
e. Skin carcinoma	3	2.0	1.9	4	3.0	1.8	2	1.0	1.0	4	0.3	1.4
f. Other & unspecified	2	1.0	1.1	3	0.5	1.2	2	.	1.1	5	4.0	1.9
XII OTHER & UNSPECIFIED	2	1.0	1.2	2	1.0	0.9	4	1.0	2.6	5	0.7	2.4
a. Other specified	1	.	0.7	1	.	0.5	0	.	.	0	.	.
b. Other unspecified	1	0.0	0.5	1	0.0	0.4	4	1.0	2.6	5	0.7	2.4
TOTAL	185	1.8	112.4	271	1.7	117.0	127	1.6	76.5	211	1.4	87.0

Please consult the quality indicators for the constituent registries